HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2-methyl-4-amino-6-oxypyrimidine

a wound healing compound

Also Known As:

2-methyl-4-amino-6-hydroxypyrimidine; MAOP; Me-A-oxypyrimidine

Networked: 16 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 521
    - 2-methyl-4-amino-6-oxypyrimidine: 16

Experts

1.	Caputo, Fabrizio: 1 article (10/2023)
2.	Lisbôa, Felipe Domingos: 1 article (10/2023)
3.	Soares Pereira, Gustavo: 1 article (10/2023)
4.	de Aguiar, Rafael Alves: 1 article (10/2023)
5.	Egberts, Friederike: 1 article (10/2005)
6.	Hauschild, Axel: 1 article (10/2005)
7.	Lange-Asschenfeldt, Bernhard: 1 article (10/2005)
8.	Lischner, Stephan: 1 article (10/2005)
9.	Corno, A F: 1 article (10/2004)
10.	Lapanashvili, L V: 1 article (10/2004)

Related Diseases

1.	Infections 09/01/1979 - "The effect of prodigiozan and pyrimidine derivatives, such as methyluracyl, oxymetacyl and 2-methyl-4-amino-6-hydroxypyrimidine on the efficiency of antibiotic therapy of experimental infections caused by Staph. " 03/01/1996 - "The experiments on mice with Staphylococcus infection at the background of immune suppression due to the treatment with prednisolone or imuran showed that the use of 2-methyl-4-amino-6-oxypyrimidine, a derivative of pyrimidine, increased the animal survival, their lifespan and the efficacy of the tobramycin therapy."
2.	Colorectal Neoplasms (Colorectal Cancer) 01/01/1991 - "Phase II studies in metastatic colorectal cancer in 345 patients have demonstrated an average response rate of 36% (range 15-59%) and a prospective randomized study performed by the Mid-Atlantic Oncology Program (MAOP) has confirmed a higher response rate with 5FU infusion compared with a bolus schedule. " 04/01/1989 - "One hundred seventy-nine patients with advanced measurable colorectal cancer not previously treated with chemotherapy were entered into a prospective randomized clinical trial by the Mid-Atlantic Oncology Program (MAOP) to compare two schedules of delivery for single-agent fluorouracil (5-FU). " 01/01/1991 - "One hundred eighty-four patients with advanced measurable colorectal cancer not previously treated with chemotherapy were entered into a prospective randomized clinical trial by the Mid-Atlantic Oncology Program (MAOP) to assess the value of weekly cisplatin (20 mg/m2) when added to a protracted schedule of 5-fluorouracil (5-FU) infusion (PIF) at 300 mg/m2/d for 10 weeks of every 12 weeks. "
3.	Neoplasms (Cancer) 09/01/1989 - "The Mid-Atlantic Oncology Program (MAOP) compared clinical trial data collected by circuit riding data managers (CDMs) from the MAOP statistical center with data collected by local data managers (LDMs) from clinics and practices, the latter being the standard data capture method in cancer clinical trials. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/1995 - "Etoposide plus cisplatin followed by thoracic radiation for stage IIIB non-small cell lung cancer: MAOP study 2188."
5.	Arterial Occlusive Diseases (Arterial Occlusive Disease) 10/18/2023 - "Methods: Study I; 1) PrC test-retest at rest and during swimming ergometer exercise; 2) BFR at rest with TrC inflated to different percentages of the minimum arterial occlusion pressure (MAOP; 60, 80, 100, 120 and 140%). "

Related Drugs and Biologics

1.	pyrimidine
2.	Tobramycin (Nebcin)
3.	Prednisolone (Predate)
4.	Azathioprine (Imuran)
5.	Fluorouracil (Carac)
6.	Cisplatin (Platino)
7.	Etoposide (VP 16)
8.	Anti-Bacterial Agents (Antibiotics)
9.	2-methyl-4-amino-6-oxypyrimidine
10.	Photosensitizing Agents (Photosensitizers)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)